CN105663131A - Repaglinide and metformin hydrochloride tablet pharmaceutical composition and preparation method thereof - Google Patents
Repaglinide and metformin hydrochloride tablet pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN105663131A CN105663131A CN201610009632.3A CN201610009632A CN105663131A CN 105663131 A CN105663131 A CN 105663131A CN 201610009632 A CN201610009632 A CN 201610009632A CN 105663131 A CN105663131 A CN 105663131A
- Authority
- CN
- China
- Prior art keywords
- repaglinide
- granule
- metformin
- preparation
- microcrystalline cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 title claims abstract description 150
- 229960002354 repaglinide Drugs 0.000 title claims abstract description 150
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 229960004329 metformin hydrochloride Drugs 0.000 title claims abstract description 46
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 33
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 33
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 33
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 31
- 238000002156 mixing Methods 0.000 claims abstract description 25
- 239000002245 particle Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000008187 granular material Substances 0.000 claims description 110
- 229960003105 metformin Drugs 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 21
- 239000012530 fluid Substances 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 18
- 229920003081 Povidone K 30 Polymers 0.000 claims description 14
- 239000004744 fabric Substances 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 12
- 229960000540 polacrilin potassium Drugs 0.000 claims description 11
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 11
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 10
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 10
- 229960003194 meglumine Drugs 0.000 claims description 10
- 229920001983 poloxamer Polymers 0.000 claims description 10
- 229960000502 poloxamer Drugs 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 239000007779 soft material Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 238000001125 extrusion Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 17
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012467 final product Substances 0.000 description 7
- HPWIKAVXRHCHPE-BQAIUKQQSA-N CN(C)C(=N)N=C(N)N.C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 Chemical compound CN(C)C(=N)N=C(N)N.C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 HPWIKAVXRHCHPE-BQAIUKQQSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001360 synchronised effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000003578 releasing effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 101001050984 Apple stem grooving virus (strain Korea) Putative movement protein Proteins 0.000 description 1
- 101001050983 Apple stem grooving virus (strain P-209) Probable movement protein Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000029152 Small face Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000004283 biguanides Chemical group 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940127021 low-dose drug Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940036936 metformin and repaglinide Drugs 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical group CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a repaglinide and metformin hydrochloride tablet pharmaceutical composition; in a prescription, the amount of a disintegrating agent is greatly reduced compared with the prior art; in a process, microcrystalline cellulose particles are prepared in advance, repaglinide is made into a solution, repaglinide particles are prepared on the microcrystalline cellulose particles through fluidized bed atomizing, and the repaglinide particles are mixed and tabletted with metformin hydrochloride particles. The prepared repaglinide and metformin hydrochloride tablet product is stable, the insoluble drug repaglinide and the water-soluble drug metformin hydrochloride are both released synchronously according to requirements, and the bioavailability is better compared with that of the prior art; and at the same time, the problem of uneven mixing of the low-dosage drug repaglinide is solved, and the drug efficacy playing is greatly promoted.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of repaglinide metformin tablet medicament composition and preparation method thereof.
Background technology
Repaglinide diformin tablet, principal agent composition is repaglinide and metformin hydrochloride. Repaglinide, chemistry S by name (+)-2-ethyoxyl-4-{2-[(3-methyl isophthalic acid-(2-(piperidino) phenyl) butyl) amino]-2-oxoethyl benzoic acid, chemical structural formula is:
Metformin, clinically its hydrochlorate conventional, i.e. metformin hydrochloride, chemistry 1,1-Dimethylbiguanide hydrochloride by name, chemical structural formula is:
The compound of repaglinide and metformin hydrochloride can control blood sugar content from two different approaches. Metformin hydrochloride is biguanide antidiabetic medicament, and it reduces glycogen output by suppressing gluconeogenesis function of liver, suppresses intestinal wall cellular uptake glucose simultaneously, can be obviously improved resistance to sugar amount and the hyperinsulinemia of patient, improve the human body natural reaction to insulin; Different from insulin action, it, without the effect promoting lipogenesis, to normal person without obvious hypoglycemic activity, therefore, does not generally cause hypoglycemia. Repaglinide is non-sulfonylurea Insulin-secreting agent, its 36KDA protein-specific on the potassium-channel of the outer dependency ATP of d cell film is combined, potassium channel is made to close, D cell depolarization, calcium channel is open, flow of calcium ions, promotes Postprandial insulin secretion, thus comparatively fast reducing by 2 hours blood glucoses (PPG) after the meal. Papillary has good cooperative effect, more can efficiently control blood glucose than independent medication, and therefore, exploitation compound Repaglinide metformin hydrochloride tablet can bring good economic benefit and social benefit.
Those skilled in the art are devoted to the compound preparation of exploitation repaglinide and metformin hydrochloride. But owing to repaglinide dissolubility is little, the dissolubility in water is 0.005mg/mL, and metformin hydrochloride is water soluble drug, repaglinide will can not discharge out if metformin hydrochloride rate of releasing drug is suitable to adopt conventional technique preparation to cause. And repaglinide rate of releasing drug is properly, the release of metformin hydrochloride will be lost control of, and cause that the prominent of metformin hydrochloride is released. Conventional technique is adopted to be difficult to meet its synchronous release requirement in vivo and in vitro. It addition, according to commercialized product it can be seen that in compound preparation the dose difference of repaglinide and metformin hydrochloride huge, the repaglinide at preparation process small faces the difficult problem that mixing is uneven.
For solving the problems referred to above, Yuan Yan house journal CN101516347A discloses a kind of pharmaceutical preparation comprising metformin and repaglinide, by before mixing repaglinide being made preformulation and this preformulation, there is the dissolution characteristic unrelated with pH value and specific relative humidity, it is dispersed in high dose highly-water-soluble metformin hydrochloride obtaining low dosage low solubility repaglinide, and both active substances can both with the effect of desired rate release. But, the technical scheme of this patent disclosure needs the strict relative humidity controlling repaglinide pre-formulation, and the adopted desiccant of this patent dry step of being responsible for a task until it is completed is dfficult to apply to produce in amplification. It addition, the releasing effect of two kinds of active ingredient in its description and in unexposed obtained compositions, and the information such as its bioavailability in vivo. Those skilled in the art cannot be known, adopts whether the technical scheme of this patent disclosure can reach its technique effect improving release declared.
Chinese patent CN103251593A discloses a kind of pharmaceutical composition comprising repaglinide and metformin hydrochloride. This patent adopts the previously prepared granule I containing repaglinide, repaglinide and alkaline agent, solubilizing agent, suitable amount of adhesive are dissolved in suitable quantity of water and make solution, by in this spray solution to appropriate filler such as silica sol, it is sufficiently mixed uniformly, it is dried to the moisture granule lower than 2%, again this dry particulate abrasive is become the granularity fine powder less than 80 orders, obtain granule I. The repaglinide diformin tablet uniformity of dosage units A+1.8S=8.3 that this patent system obtains. Owing to the method needs strictly to control pellet moisture, and needing grinding to control particle diameter, production operation requires higher, and in process of lapping, loss is bigger.
Chinese patent CN103070864A provides one and prepares repaglinide metformin drug formulation process. Repaglinide, meglumine, poloxamer and polyvidone are dissolved in 50% ethanol, metformin hydrochloride and certain adjuvant are placed in fluid bed and carry out hot melt granulation; Then repaglinide solution is sprayed in fluid bed, carry out one-step palletizing. Hot melt is granulated and is combined with one-step palletizing technology by this operation, operate easier, then research finds that repaglinide exists interaction with metformin, adopt this operational approach, repaglinide solution Direct spraying is on metformin granule, increase both contact surfaces, accelerate it and react to each other, be unfavorable for that product is stable.
Chinese patent CN101843617A discloses the compound slow release preparation of a kind of repaglinide metformin hydrochloride. By adding a certain amount of framework material respectively in repaglinide and metformin hydrochloride, it is prepared into slow releasing preparation, thus solving insoluble drug repaglinide and the problem of water soluble drug metformin hydrochloride synchronous slow. But the slow-release material price needed for preparing compound slow release preparation is costly, the requirement of preparation equipment is also higher, thus adding production cost.
Summary of the invention
It is an object of the invention to provide a kind of repaglinide metformin tablet medicament composition, under guaranteeing the premise that product is stable, it is achieved insoluble drug repaglinide and water soluble drug metformin hydrochloride synchronous release all on request; Solve the problem that the mixing of low-dose drugs repaglinide is uneven simultaneously.
For achieving the above object, the present invention provides a kind of repaglinide metformin tablet medicament composition, and in the pharmaceutical composition of per unit preparation, the quality of each component is:
Further, in the pharmaceutical composition of per unit preparation, the quality of each component is:
Or, in the pharmaceutical composition of per unit preparation, the quality of each component is:
Or, in the pharmaceutical composition of per unit preparation, the quality of each component is:
Or, in the pharmaceutical composition of per unit preparation, the quality of each component is:
Or, in the pharmaceutical composition of per unit preparation, the quality of each component is:
Or, in the pharmaceutical composition of per unit preparation, the quality of each component is:
Or, in the pharmaceutical composition of per unit preparation, the quality of each component is:
The preparation method that present invention also offers a kind of above-mentioned repaglinide metformin tablet medicament composition, comprises the following steps:
(1) preparing repaglinide solution: the poloxamer of recipe quantity, meglumine and PVP K30 are added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into the repaglinide of recipe quantity, continuously stirred makes dissolving, prepares repaglinide solution;
(2) preparing repaglinide granule: the microcrystalline cellulose crude granule taking recipe quantity is placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.0～2.0Pa, starts solution feed pump, is sprayed in fluid bed by the repaglinide solution that step (1) prepares and granulates, after hydrojet completes, dry, obtains repaglinide granule;
(3) metformin granule is prepared: take the metformin hydrochloride of recipe quantity, add the PVP K30 of recipe quantity, sorbitol, polyethylene glycol 6000, it is placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, it is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule;
(4) the metformin granule that the repaglinide granule that blend step (2) prepares prepares with step (3), hybrid particles adds the polacrilin potassium of recipe quantity, microcrystalline Cellulose, mixing 20min, add the magnesium stearate of recipe quantity, be mixed to get total mixed granule;
(5) tabletting.
Wherein, the present invention prepares microcrystalline cellulose crude granule by the following method: be sequentially added in granulation pot by microcrystalline Cellulose and PVP K30, mixes 10min; Slowly add water in stirring simultaneously, soft material processed; Being extruded by the soft material extruder of preparation, hole diameter of sieve (perforated) plate is 0.8mm, the material of extrusion is proceeded to spheronizator and carries out round as a ball, rotating speed 160～300rpm; Round as a ball material is proceeded to drying machine, and inlet temperature is set to 50～70 DEG C, when moisture is 2%～8%, stops dry; The dried granule screen cloth of 40～60 orders is sieved, obtains microcrystalline cellulose crude granule.
Repaglinide metformin tablet medicament composition prepared by the present invention has the advantage that
(1) in prescription of the present invention, the consumption relatively prior art of polacrilin potassium greatly reduces, in obtained repaglinide diformin tablet, the repaglinide of slightly solubility and water miscible metformin hydrochloride all can according to each requiring synchronous release, dissolved corrosion is good, is conducive to medicine to absorb in vivo;
(2) previously prepared microcrystalline cellulose crude granule, again repaglinide is configured to solution, bed spray is adopted to prepare repaglinide granule on microcrystalline cellulose crude granule, improve the problem that the mixing of low dosage repaglinide is uneven, be conducive to repaglinide Fast Stripping simultaneously, the performance of drug effect is greatly facilitated;
(3), in repaglinide particulate production of the present invention, do not need its moisture and grain graininess are controlled especially, easy and simple to handle, be conducive to the big production of socialization;
(4) prepare repaglinide granule and metformin granule respectively, remix, decrease the contact of two active component to greatest extent, it is to avoid it interacts, improve product stability.
Detailed description of the invention
Below in conjunction with test example and embodiment, the present invention is described in further detail, but not limitation of the present invention, the equivalent replacement of all any this areas made according to the disclosure of invention, belong to protection scope of the present invention.
Microcrystalline cellulose crude granule prepares example:
51g microcrystalline Cellulose and 9g PVP K30 are sequentially added in granulation pot and mix 10min; Slowly add water in stirring simultaneously, soft material processed; Being extruded by the soft material extruder of preparation, hole diameter of sieve (perforated) plate is 0.8mm, the material of extrusion is proceeded to spheronizator and carries out round as a ball, rotating speed 160～300rpm; Round as a ball material is proceeded to drying machine, and inlet temperature is set to 50～70 DEG C, when moisture is 2%～8%, stops dry;Being sieved by the dried granule screen cloth of 40～60 orders, obtain microcrystalline cellulose crude granule, yield is 90%, for following example.
Embodiment 1: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.2g poloxamer, 0.5g meglumine and 0.6g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 1g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 15g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.0Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 16g PVP K30,8g sorbitol, 4g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule; Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 4.5g polacrilin potassium, 10g microcrystalline Cellulose, mixes 20min, add 1g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Embodiment 2: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.9g poloxamer, 1.0g meglumine and 1.2g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 2g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 36g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.5Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 22g PVP K30,12g sorbitol, 6g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule; Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 9.0g polacrilin potassium, 20g microcrystalline Cellulose, mixes 20min, add 3g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Embodiment 3: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.9g poloxamer, 1.0g meglumine and 1.2g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 1g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 36g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 2.0Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 20g PVP K30,10g sorbitol, 5g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule;Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 9.0g polacrilin potassium, 20g microcrystalline Cellulose, mixes 20min, add 3g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Embodiment 4: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.9g poloxamer, 1.0g meglumine and 1.2g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 2g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 36g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.6Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 20g PVP K30,10g sorbitol, 5g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule; Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 9.0g polacrilin potassium, 20g microcrystalline Cellulose, mixes 20min, add 3g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Embodiment 5: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.4g poloxamer, 0.8g meglumine and 0.6g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 2g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 30g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.0Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 20g PVP K30,9g sorbitol, 4g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule; Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 7.5g polacrilin potassium, 18g microcrystalline Cellulose, mixes 20min, add 2g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Embodiment 6: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.6g poloxamer, 0.5g meglumine and 1.0g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 1g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 25g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 2.0Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 18g PVP K30,11g sorbitol, 6g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule;Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 5.5g polacrilin potassium, 15g microcrystalline Cellulose, mixes 20min, add 2g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Embodiment 7: repaglinide metformin tablet recipe (in 1000, unit: g):
Preparation technology:
0.5g poloxamer, 0.7g meglumine and 1.0g PVP K30 being added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into 2g repaglinide, continuously stirred makes dissolving, prepares repaglinide solution; Taking 20g microcrystalline cellulose crude granule to be placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.2Pa, starts solution feed pump, is sprayed in fluid bed by repaglinide solution and granulate, and hydrojet is dry after completing, and obtains repaglinide granule; Take 500g metformin hydrochloride, add 18g PVP K30,9g sorbitol, 6g polyethylene glycol 6000, be placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, and is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule; Repaglinide granule and metformin granule are added in mixed-hopper, mixes 20min, hybrid particles adds 8.5g polacrilin potassium, 16g microcrystalline Cellulose, mixes 20min, add 2g magnesium stearate, be mixed to get total mixed granule; Tabletting, to obtain final product.
Comparative formulation 1: prescription and technique with reference to Chinese patent CN101516347A embodiment 2 prepare Comparative formulation 1, specification: repaglinide/metformin hydrochloride (2mg/500mg);
Comparative formulation 2: prescription and technique with reference to Chinese patent CN103070864A embodiment 1 prepare Comparative formulation 2, and specification is: repaglinide/metformin hydrochloride (1mg/500mg). What adopt HPLC method mensuration Comparative formulation 2 has related substance, and wherein the total impurities of repaglinide is 0.59%, the total impurities of metformin is 0.47%.
Test example 1 mixing uniformity contrasts
Owing in compound preparation, the repaglinide of low dosage exists the problem being difficult to mix homogeneously, it is therefore desirable to the mixing uniformity of repaglinide in hybrid particles is investigated. Prepare the embodiment of the present invention 1,2,3,4 and Comparative formulation 1 sample respectively, and the mixing uniformity of repaglinide in total mixed granule before investigating tabletting, result of the test is as shown in table 1.
Mixing uniformity assay method: in the upper left corner of mixer upper surface, the lower right corner and intermediate point, the intermediate point in intermediate layer, the lower left corner of lower surface, the upper right corner and intermediate point sampling, measure the content of each sample point repaglinide, calculate the RSD% of 7 groups of assay results.
Table 1 embodiment of the present invention and repaglinide mixing uniformity contrast in Comparative formulation
| Sequence number | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Comparative formulation 1 |
| Sample point 1 | 100.6% | 98.6% | 99.2% | 98.6% | 103.4% |
| Sample point 2 | 98.9% | 100.5% | 98.5% | 99.5% | 94.5% |
| Sample point 3 | 99.1% | 99.2% | 99.3% | 98.7% | 102.6% |
| Sample point 4 | 98.5% | 99.5% | 100.8% | 100.9% | 95.4% |
| Sample point 5 | 100.8% | 98.8% | 99.6% | 99.1% | 93.4% |
| Sample point 6 | 99.5% | 98.3% | 100.7% | 100.6% | 92.8% |
| Sample point 7 | 98.7% | 100.6% | 98.6% | 99.7% | 102.7% |
| RSD% | 0.92% | 0.91% | 0.92% | 0.90% | 4.93% |
It is shown that the RSD% that in each sample point sample of the embodiment of the present invention 1,2,3,4 sample, repaglinide mixing uniformity measures is all less than 0.92%, hybrid particles is highly uniform;And repaglinide content difference is very big in each sample point of Comparative formulation 1 sample, the RSD% that mixing uniformity measures is 4.93%, it is far longer than the RSD% value of embodiment of the present invention sample, it is seen that the mixed effect of embodiment of the present invention sample particle is significantly better than Comparative formulation 1 sample.
Test example 2 influence factor tests
Take the embodiment of the present invention 3,4 sample and Comparative formulation 1 sample, at high temperature (60 DEG C), high humidity (25 DEG C, RH92.5%) place 10 days under, illumination (4500 ± 500Lx) condition, carry out content respectively at sampling in the 0th day, 10 days, have the uniformity of dosage units (according to the 4th general rule 0941 of " Chinese Pharmacopoeia " version in 2015) of related substance, dissolution (with pH5.0 citric acid phosphate buffer 900ml for dissolution medium) and repaglinide to measure, investigating sample mass change situation under these conditions, result of the test is referring to table 2.
Table 2 embodiment of the present invention compares with Comparative formulation influence factor's test mass
Note: what have related substance record is total impurities amount (%).
It is shown that when 0 day, in the embodiment of the present invention 3,4 sample and Comparative formulation 1 sample, the content of repaglinide and metformin hydrochloride two active component was without being clearly distinguished from, after placing 10 days in each condition, also have no significant change;
In having related substance, in the embodiment of the present invention 3,4 sample metformin hydrochloride have related substance to place 10 days under 0 day and high temperature, high humidity, illumination condition after, all convert, illustrate highly stable. Repaglinide in the embodiment of the present invention 3,4 sample had related substance when 0 day, and respectively 0.08%, 0.07%, all increase to some extent after placing 10 days when influence factor, rise between 0.12%～0.22%. And repaglinide and metformin hydrochloride were when 0 day in Comparative formulation 1 sample, there is related substance to be all significantly greater than embodiment of the present invention sample, after especially repaglinide places 10 days in each condition, have related substance significantly to increase, reach 0.49%. Visible, the embodiment of the present invention 3,4 sample relatively Comparative formulation 1 sample is stable.
In dissolution, in the embodiment of the present invention 3,4 sample, repaglinide and metformin hydrochloride all can the complete dissolutions when 15min, the dissolution of repaglinide reaches more than 97.2%, the dissolution of metformin hydrochloride reaches more than 97.4%, and after placing 10 days under high temperature, high humidity and illumination condition, there is not significant change; And repaglinide was when 0 day in Comparative formulation 1 sample, dissolution is relatively slow, the dissolution only 89.3% when 15min, and after placing 10 days under conditions of high humidity, dissolution decreases. Visible, the embodiment of the present invention 3,4 sample is significantly improved compared with the dissolution of repaglinide in Comparative formulation 1 sample.
In repaglinide uniformity of dosage units, when 0 day, in the embodiment of the present invention 3,4 sample, the evaluating A+2.2S value of repaglinide Determination of Content Uniformity is only 3.01% and 2.99%, much smaller than in Comparative formulation 1 sample the 8.02% of repaglinide A+2.2S value; And after placing 10 days under high temperature, high humidity and illumination condition, the uniformity of dosage units A+2.2S value of the embodiment of the present invention 3,4 sample repaglinide slightly increases, but amplification is all less; And after Comparative formulation 1 sample places 10 days in each condition, A+2.2S value increases to 9.46%, it is seen then that in embodiment of the present invention sample, repaglinide composition mixing homogeneity is significantly better than Comparative formulation 1 sample.
Test example 3 beasle dog pharmacokinetic trial
1, test objective
Under the molar doses such as investigation, the concentration level of repaglinide and metformin and basic pharmacokinetic characteristics thereof in blood plasma after beasle dog single oral administration embodiment 1,3,4 sample and Comparative formulation 1 sample, and compare major parameter Cmax, Tmax, T1/2, AUClastDeng difference.
2, material and method
2.1, test medicine
Embodiment 1 sample: adopting the sample that the embodiment of the present invention 1 prepares, specification is repaglinide/metformin hydrochloride (1mg/500mg);
Embodiment 3 sample: adopting the sample that the embodiment of the present invention 3 prepares, specification is repaglinide/metformin hydrochloride (1mg/500mg);
Embodiment 4 sample: adopting the sample that the embodiment of the present invention 4 prepares, specification is repaglinide/metformin hydrochloride (2mg/500mg);
Comparative formulation 1: prescription and technique with reference to Chinese patent CN101516347A embodiment 2 prepare Comparative formulation 1, specification: repaglinide/metformin hydrochloride (2mg/500mg).
2.2, experimental animal:
Beagle dog 8, male and female half and half, body weight 10 ± 2kg, age 10-12 month;
2.3, EXPERIMENTAL DESIGN
Adopting 2 × 4 cross matchings, single test is totally 4 cycles, completes single test every kind preparation totally 8 samples, as shown in the table in detail:
Table 3 Repaglinide-metformin hydrochloride Beagle dog pharmacokinetic trial designs
The female Beagle dog of remarks: MD male Beagle dog FD
2.4, blood sampling point design
Before administration, after administration, 5min, 15min, 30min, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h take blood 1mL in forelimb or hind leg vein, it is placed in EDTA-K2 pipe, 4 DEG C of low temperature 3000r/min, centrifugal 10min, separated plasma ,-70 DEG C of refrigerator freezings preserve. After each periodic test terminates, there are 3 days elimination phases, after the complete metabolism of medicine is complete, then carry out the test of next cycle.
3, result of the test and statistics
3.1, key data
After table 4 beasle dog single oral embodiment 1,3,4 and Comparative formulation 1 sample
The pharmacokinetic parameter of metformin in blood plasma
After table 5 beasle dog single oral embodiment 1,3,4 and Comparative formulation 1 sample
The pharmacokinetic parameter of repaglinide in blood plasma
Note: F relative bioavailability
4, conclusion (of pressure testing)
By table 4, table 5 test data it can be seen that compared with Comparative formulation 1, after beasle dog single oral embodiment 1 sample, the parameters of repaglinide and metformin all increases to some extent, and relative bioavailability relatively Comparative formulation 1 increases; After beasle dog single oral embodiment 3,4 sample, the C of repaglinide and metforminmax、AUClastDramatically increasing with relative bioavailability all relatively Comparative formulation 1, bioavailability is improved significantly. Visible embodiment of the present invention sample, especially embodiment 3,4 sample are compared Comparative formulation 1 sample quality and are significantly improved.
In sum, the present invention greatly reduces the prescription consumption of polacrilin potassium compared with prior art, adopt previously prepared microcrystalline cellulose crude granule, again repaglinide is configured to solution, on microcrystalline cellulose crude granule, repaglinide granule is prepared by bed spray, ensure that the repaglinide of slightly solubility and water miscible metformin hydrochloride are all according to each requiring synchronous release, dissolved corrosion is good, and bioavailability is more excellent compared with prior art; Improve the problem that the mixing of low dosage repaglinide is uneven simultaneously, the performance of drug effect is greatly facilitated; And the present invention eliminates subpackage repaglinide granule in prior art in preparation process, step with desiccant bag its moisture of drying control, do not need the moisture of repaglinide granule is controlled especially, also without controlling grain diameter, enormously simplify production operation, be more beneficial for the big production of socialization.Repaglinide and metformin granule remix after granulating respectively, it is to avoid two active component directly contact, and reduce the risk occurring to interact. Adopt repaglinide diformin tablet content prepared by technical scheme provided by the invention uniform, two kinds of active component energy synchronous release, and internal pharmacokinetics effect is substantially better than prior art.
Claims (10)
1. a repaglinide metformin tablet medicament composition, it is characterised in that in per unit preparation, the quality of each component is:
2. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
3. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
4. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
5. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
6. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
7. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
8. repaglinide metformin tablet medicament composition according to claim 1, it is characterised in that in per unit preparation, the quality of each component is:
9. the preparation method of the repaglinide metformin tablet medicament composition described in an any one of claim 1～8, it is characterised in that comprise the following steps:
(1) preparing repaglinide solution: the poloxamer of recipe quantity, meglumine and PVP K30 are added in suitable quantity of water, stirring makes material be completely dissolved, and is slow added into the repaglinide of recipe quantity, continuously stirred makes dissolving, prepares repaglinide solution;
(2) preparing repaglinide granule: the microcrystalline cellulose crude granule taking recipe quantity is placed in fluid bed top spray pot, set inlet temperature as 40～60 DEG C, air intake flow is 60～150m3/ h, atomizing pressure is 1.0～2.0Pa, starts solution feed pump, is sprayed in fluid bed by the repaglinide solution that step (1) prepares and granulates, after hydrojet completes, dry, obtains repaglinide granule;
(3) metformin granule is prepared: take the metformin hydrochloride of recipe quantity, add the PVP K30 of recipe quantity, sorbitol, polyethylene glycol 6000, it is placed in granulation pot, mixing 10min, stirring is slowly added into suitable quantity of water simultaneously and granulates, it is 1.0mm screen cloth granulate with hole diameter of sieve (perforated) plate, dry, obtain metformin granule;
(4) the metformin granule that the repaglinide granule that blend step (2) prepares prepares with step (3), hybrid particles adds the polacrilin potassium of recipe quantity, microcrystalline Cellulose, mixing 20min, add the magnesium stearate of recipe quantity, be mixed to get total mixed granule;
(5) tabletting.
10. preparation method according to claim 9, it is characterised in that described microcrystalline cellulose crude granule adopts following methods to prepare: be sequentially added in granulation pot by microcrystalline Cellulose and PVP K30, mixes 10min; Slowly add water in stirring simultaneously, soft material processed; Being extruded by the soft material extruder of preparation, hole diameter of sieve (perforated) plate is 0.8mm, the material of extrusion is proceeded to spheronizator and carries out round as a ball, rotating speed 160～300rpm;Round as a ball material is proceeded to drying machine, and inlet temperature is set to 50～70 DEG C, when moisture is 2%～8%, stops dry; The dried granule screen cloth of 40～60 orders is sieved, obtains microcrystalline cellulose crude granule.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511031680 | 2015-12-31 | ||
| CN2015110316804 | 2015-12-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105663131A true CN105663131A (en) | 2016-06-15 |
| CN105663131B CN105663131B (en) | 2017-04-05 |
Family
ID=56299377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610009632.3A Active CN105663131B (en) | 2015-12-31 | 2016-01-08 | A kind of Repaglinide metformin tablet medicament composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105663131B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109428A (en) * | 2016-07-22 | 2016-11-16 | 江苏豪森药业集团有限公司 | The preparation process of repaglinide metformin |
| WO2018034627A1 (en) * | 2016-08-18 | 2018-02-22 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Pharmaceutical composition of antidiabetic tablet |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103371981A (en) * | 2012-04-26 | 2013-10-30 | 天津药物研究院 | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof |
| CN103385878A (en) * | 2013-07-24 | 2013-11-13 | 山东省医药工业研究所 | Repaglinide and dimethyldiguanide pharmaceutical composition and preparation method thereof |
-
2016
- 2016-01-08 CN CN201610009632.3A patent/CN105663131B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103371981A (en) * | 2012-04-26 | 2013-10-30 | 天津药物研究院 | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof |
| CN103385878A (en) * | 2013-07-24 | 2013-11-13 | 山东省医药工业研究所 | Repaglinide and dimethyldiguanide pharmaceutical composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 杨欣等: "瑞格列奈二甲双胍片制备工艺研究", 《中国药师》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109428A (en) * | 2016-07-22 | 2016-11-16 | 江苏豪森药业集团有限公司 | The preparation process of repaglinide metformin |
| CN106109428B (en) * | 2016-07-22 | 2019-06-21 | 江苏豪森药业集团有限公司 | The preparation process of Repaglinide melbine |
| WO2018034627A1 (en) * | 2016-08-18 | 2018-02-22 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Pharmaceutical composition of antidiabetic tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105663131B (en) | 2017-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101141961B (en) | Stable particular pharmaceutical composition of solifenacin or salt thereof | |
| TW201023857A (en) | Pharmaceutical composition for modified release | |
| CN102319245B (en) | Composition containing repaglinide and metformin hydrochloride and preparation thereof | |
| CN103655570B (en) | Sitagliptin and metformin compound slow release preparation and preparation method thereof | |
| CN107669683B (en) | Pharmaceutical composition containing sitagliptin and metformin | |
| CN103919746A (en) | Edoxaban sustained release tablet and preparation method thereof | |
| CN103845326B (en) | Compound of vildagliptin and melbine and preparation method thereof | |
| CN103181923B (en) | Pharmaceutical preparation comprising Repaglinide and preparation method thereof | |
| CN105582008A (en) | Composition containing vildagliptin and metformin and preparation method of composition | |
| CN103479592A (en) | Metformin hydrochloride sustained release tablets and preparation method thereof | |
| WO2013169007A1 (en) | Sustained-release complex preparations for treating diabetes with improved drug compliance and method for preparing same | |
| CN105663131B (en) | A kind of Repaglinide metformin tablet medicament composition and preparation method thereof | |
| CN102349915B (en) | Acetaminophen, caffeine, chlorphenamine maleate, and vitamin C preparation and preparation method thereof | |
| CN108030770A (en) | Controllable dry suspensoid agent of drug release containing drug-resin complex and preparation method thereof | |
| CN102416003A (en) | Method for preparing entecavir tablets | |
| CN103705515B (en) | The preparation method of the pharmaceutical composition that contains Repaglinide and Metformin hydrochloride | |
| CN106924237A (en) | A kind of pharmaceutical composition of and Metformin hydrochloride net containing En Gelie | |
| CN103735544B (en) | A kind of preparation technology of vildagliptin/metformin hydrochloride compound preparation | |
| CN104224783B (en) | A kind of pharmaceutical composition of the melbine containing Repaglinide and preparation method thereof | |
| CN103505466B (en) | Solid compound preparation containing metformin hydrochloride and glimepiride and its production and use | |
| CN107213130B (en) | A kind of Entecavir Pharmaceutical composition, preparation method and applications | |
| CN103463090A (en) | Preparation method of sitagliptin metformin hydrochloride compound preparation | |
| CN103385878A (en) | Repaglinide and dimethyldiguanide pharmaceutical composition and preparation method thereof | |
| CN102579358B (en) | A kind of drug sustained-release pellet and preparation method thereof | |
| CN102218064B (en) | Pharmaceutical combination with repaglinide and metformin as active components and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |